<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010341</article-id><article-id pub-id-type="publisher-id">ACM-38109</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_58618216.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  阿尔茨海默病的临床研究进展
  Clinical Research Progress of Alzheimer’s Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓峰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>司</surname><given-names>冰心</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>广才</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>文津</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>空军特色医学中心门诊部保健诊疗科，北京</addr-line></aff><aff id="aff2"><addr-line>解放军总医院京东医疗区光明桥门诊部保健科，北京</addr-line></aff><aff id="aff4"><addr-line>空军特色医学中心干部病房神经内科，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2254</fpage><lpage>2259</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    阿尔茨海默病(Alzheimer’s disease, AD)是一种进行性，不可逆转，无法治愈的神经退行性疾病，是痴呆最常见的一种。患者主要症状是认知功能持续降低，功能性自立丧失，行为改变，需要人员护理。在我国，由于患者和家属对本病认识的局限，70%的患者确诊时已为重度，错过了最佳干预和治疗时机，到目前为止，还没有一种能够预防或减缓疾病进展的药物。老年痴呆也被称为“无声威胁”，正成为最昂贵的疾病之一，本文对AD的临床研究进展作一综述。&lt;br/&gt;Alzheimer’s disease is a progressive, irreversible, incurable, neurodegenerative illness and the most common of the dementing disorders. Slow decline caused by this disease, is characterized by cognitive deterioration, loss of functional independence, changes in behaviour, and expanding needs for care. In our country, due to the limitation of patients’ and their families’ understanding of the disease, 70% of the patients have been diagnosed as severe and missed the best opportunity for intervention and treatment. AD is becoming one of the most problematic and expensive illnesses for the civilization, also known as “silent threat”. This paper has summarized these research achievements of AD. 
  
 
</p></abstract><kwd-group><kwd>阿尔茨海默病，病因，临床研究，综述, Alzheimer Disease</kwd><kwd> Pathogenesis</kwd><kwd> Research Achievement</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>阿尔茨海默病(Alzheimer’s disease, AD)是一种进行性，不可逆转，无法治愈的神经退行性疾病，是痴呆最常见的一种。患者主要症状是认知功能持续降低，功能性自立丧失，行为改变，需要人员护理。在我国，由于患者和家属对本病认识的局限，70%的患者确诊时已为重度，错过了最佳干预和治疗时机，到目前为止，还没有一种能够预防或减缓疾病进展的药物。老年痴呆也被称为“无声威胁”，正成为最昂贵的疾病之一，本文对AD的临床研究进展作一综述。</p></sec><sec id="s2"><title>关键词</title><p>阿尔茨海默病，病因，临床研究，综述</p></sec><sec id="s3"><title>Clinical Research Progress of Alzheimer’s Disease</title><p>Xiaofeng Li<sup>1</sup>, Bingxin Si<sup>2</sup>, Guangcai Wang<sup>1</sup>, Wenjin Du<sup>3</sup></p><p><sup>1</sup>Guangming Bridge Clinic Jingdong Medical District PLA General Hospital, Beijing</p><p><sup>2</sup>Department of Health Care, Air Force Medical Center, Beijing</p><p><sup>3</sup>Department of Neurology, Cadre Ward, Air Force Medical Center, Beijing</p><p><img src="//html.hanspub.org/file/8-1571591x4_hanspub.png" /></p><p>Received: Sep. 28<sup>th</sup>, 2020; accepted: Oct. 13<sup>th</sup>, 2020; published: Oct. 20<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/8-1571591x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Alzheimer’s disease is a progressive, irreversible, incurable, neurodegenerative illness and the most common of the dementing disorders. Slow decline caused by this disease, is characterized by cognitive deterioration, loss of functional independence, changes in behaviour, and expanding needs for care. In our country, due to the limitation of patients’ and their families’ understanding of the disease, 70% of the patients have been diagnosed as severe and missed the best opportunity for intervention and treatment. AD is becoming one of the most problematic and expensive illnesses for the civilization, also known as “silent threat”. This paper has summarized these research achievements of AD.</p><p>Keywords:Alzheimer Disease, Pathogenesis, Research Achievement, Review</p><disp-formula id="hanspub.38109-formula34"><graphic xlink:href="//html.hanspub.org/file/8-1571591x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-1571591x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-1571591x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>AD是痴呆中最常见的一种，几乎占所有痴呆病的70%，其患病率随着年龄的增长而增加，在AD患者中，65岁以上人群占10%和85岁以上人群占50% [<xref ref-type="bibr" rid="hanspub.38109-ref1">1</xref>]。随着人口老龄化的到来，到2025年，预计我国AD的人群将达到2千万。在医疗保健类疾病中高发病率，高死亡率，高治疗和护理成本使AD超过心血管疾病甚至比肩癌症，成为全社会关注的社会问题。到目前为止，还没有治疗AD的特效药，对AD患者来说无论是本人还是家里人都是痛苦的，因为几乎没有哪种病像AD病人一样需要家属长期的照顾和情感参与，所以AD成为以神经内科为主的多学科研究的热点。</p></sec><sec id="s6"><title>2. 病因及发病机理</title><p>大多数AD病人都没有明确的病因或致病因素，发病机制尚未完全阐明，脑病变主要见于内侧颞叶，其次为海马及海马旁回，杏仁核，丘脑与后扣带回及梭状回也存在病变 [<xref ref-type="bibr" rid="hanspub.38109-ref2">2</xref>]。</p><sec id="s6_1"><title>2.1. 遗传基因</title><p>在AD的致病因素中，家族患者有明确的遗传因素，他们以常染色体显性突变方式传播疾病，已经检测到多代称为家族性AD。对其研究发现，主要有以下方面：早老素1 (Presenilins1, PS-1)和早老素2 (Presenilins2, PS-2)分别位于14号染色体即14q24.3和14q42.13上。PS-1基因突变选择性的导致纤维原性较强，易聚集的β-淀粉样蛋白(amyloid β-proteion, Aβ) Aβ42产生过多，导致AD的形成 [<xref ref-type="bibr" rid="hanspub.38109-ref3">3</xref>]，PS-2可通过对C末端肽水解酶的作用使淀粉样肽前体蛋白(APP)裂解，促进Aβ生成增多 [<xref ref-type="bibr" rid="hanspub.38109-ref4">4</xref>]。淀粉样肽前体蛋白(APP)，位于21号染色体即21q21.3上，在生理条件下编码APP可裂解为可溶性的β-淀粉样肽前体蛋白(β-APP)，再进一步被γ-分解酶裂解。而当某些原因，导致APP基因突变时β-APP经胞质内溶酶体内的β-，γ-分泌酶作用裂解为Aβ [<xref ref-type="bibr" rid="hanspub.38109-ref5">5</xref>]，Aβ的异常沉积，引起神经元的毒性进而促进形成早老素(PS)，促进AD的发展。Tau蛋白基因位于17号染色体即17q21上，是一种微管蛋白，对微管起促进和稳定作用，主要分布在大脑的额叶，颞叶海马及内嗅区，在AD患者脑中主要为异常过度磷酸化的Tau蛋白，聚集形成神经元纤维缠结(NFT)，使神经元的功能损失加剧，引起痴呆。PS-1基因异常最常见，差不多报告了200多例，而且这些突变在所有家族性AD病例中约占50%。APP基因异常较常见，有超过30个突变的记录描述。PS-2上的突变很罕见(20个家族报道有12例) [<xref ref-type="bibr" rid="hanspub.38109-ref6">6</xref>]。AD百分之百将在这些受基因突变的人群中进展。AD的常染色体显性遗传形式通常较早开始(在他们的50 s~60 s)，与散发病例相比进展迅速。对AD家族内部具有危险基因的人群对其基因改变，以减少患病的风险。在AD患者，磷酸化的Tau蛋白是非AD患者的三倍，Aschenbrenner [<xref ref-type="bibr" rid="hanspub.38109-ref7">7</xref>] 认为tau的存在或积累是认知损害的预测因子，Hanseeuw [<xref ref-type="bibr" rid="hanspub.38109-ref8">8</xref>] 研究发现 AD患者的认知能力下降和神经退行性变主要是由tau的形成和扩散所驱动的。</p></sec><sec id="s6_2"><title>2.2. 高风险基因</title><p>载脂蛋白(APOE) ε4基因决定个体患AD的风险，在大脑中，APOE主要在星形胶质细胞中表达，在小胶质细胞中表达的程度较低 [<xref ref-type="bibr" rid="hanspub.38109-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.38109-ref10">10</xref>]。APOEε4基因位于19号染色体即19q13.2上，研究表明APOEε4能够参与Aβ的合成，影响PS形成。临床、病理、流行病学、和全基因组测序研究中都证实了APOEε4是目前唯一确定的引起迟发型AD的易感基因，携带APOEε4基因可增加8~10倍患AD风险 [<xref ref-type="bibr" rid="hanspub.38109-ref11">11</xref>]。根据AD患者基因检测及病理切片分析指出，ApoEε4基因可引起AD患者认知功能降低，并形成神经原纤维缠结。</p></sec><sec id="s6_3"><title>2.3. 其他易引起AD发病的相关因素</title><p>在最新的研究中发现，在AD的致病因素中，免疫炎症反应、疱疹病毒、脑肠轴也与AD的形成有关，Aβ蛋白能激活小胶质细胞，星型胶质细胞，释放炎症介质，引发局部炎症反应，就目前研究发现十多种细胞因子如IL-1、IL-8、TNF-α等参与AD的形成 [<xref ref-type="bibr" rid="hanspub.38109-ref12">12</xref>]；单纯疱疹病毒(HSV-1)和人类疱疹病毒6型(HHV-6)可刺激APP，使APP发生异常化，生成Aβ增多，引起AD [<xref ref-type="bibr" rid="hanspub.38109-ref13">13</xref>]。肠道菌群与中枢神经系统之间通过脑–肠轴相互影响，中枢神经系统通过影响营养有效性的饱足信号肽，影响肠道功能的内分泌物质和神经通路来控制肠道微生物组的组成，肠道菌群也可通过神经、内分泌、代谢和免疫影响中枢神经系统。肠道菌群失衡，导致外周血中的“苯丙氨酸”和“异亮氨酸”的两种代谢物质异常积累，它会诱导外周促炎性细胞(Th1)的分化和增殖，并促进它们侵润入脑。而一旦这种细胞侵润入脑，就会和脑内原有的M1型小胶质细胞共同活化，从而导致与AD相关的神经炎症发生 [<xref ref-type="bibr" rid="hanspub.38109-ref14">14</xref>]。</p></sec></sec><sec id="s7"><title>3. 临床表现</title><p>AD的主要表现是认知功能障碍,精神症状和行为障碍，独立生活功能逐渐丧失。认知功能障碍主要包括短期记忆、视空间和定向障碍，语言障碍，失认及意向性失用。精神和行为症状主要有抑郁，思维和行为改变，人格障碍，及异常饮食睡眠行为。</p><p>AD根据认知能力和日常生活能力及身体机能逐渐减退的情况，可将疾病分为轻度(早期)，中度和重度(晚期)阶段。</p><sec id="s7_1"><title>3.1. 早期阶段</title><p>在早期AD患者首发症状是近记忆障碍，都是来自遥远的记忆，早期常见的症状是语言障碍，运用语言能力下降，不能讲完整句子。视空间定向功能障碍同样发生在痴呆最初阶段，而执行功能障碍始于诊断AD阶段 [<xref ref-type="bibr" rid="hanspub.38109-ref15">15</xref>]。这些损伤随着病情的进展而恶化。在AD的早期阶段，患者可以自主地生活，参加工作。周围接触的人会发现患者语言和记忆力相关问题越来越多，走错地方，丢失物品，不能胜任计划或组织活动。在AD的初期，出现一些神经精神症状，如焦虑，冷漠，烦躁和抑郁。在这个阶段神经系统检查大多是正常的。</p></sec><sec id="s7_2"><title>3.2. 中期阶段</title><p>中度的AD患者，长时期生活紊乱并且可以持续多年。患者有情景记忆障碍，但仍然能记得有关他们生活的重要细节 [<xref ref-type="bibr" rid="hanspub.38109-ref16">16</xref>]。患者所有认知功能的方面都受到影响。AD经常需要更多的照顾。一些人可能意识到对某些事件或关于自己个人经历的遗忘。患者想不起自己家的地址或电话号码，往往走错地方和记错日期。看护人在他们进行日常起居时必须帮助他们选择合适的衣服，洗澡或准备饭菜。在这个阶段AD各种神经精神症状和睡眠模式的变化都显示出来。</p></sec><sec id="s7_3"><title>3.3. 重度(晚期)阶段</title><p>在晚期阶段，患者日常活动和个人起居都需要全面照顾。患者的所有技能都在不断恶化，大小便失禁，需要人喂饭，走路要人扶，甚至坐不稳，患者呈现缄默，肢体僵直。患者此时免疫系统全面恶化，免疫力下降，并发症出现，如：深静脉血栓、压疮、感染的风险，这些并发症也常常引起患者死亡 [<xref ref-type="bibr" rid="hanspub.38109-ref17">17</xref>]。病理反射如进食困难，鼻饲也都存在于疾病的晚期阶段。</p></sec><sec id="s7_4"><title>3.4. 特异性表现</title><p>AD还有一些特异型临床表现需要鉴别，如后部枕颞叶变异型AD患者早期会出现对目标，符号，单词，面孔等的视觉理解或识别障碍；少词变异型AD患者早期会出现进行性单词检索障碍和句子复述障碍；额部变异型患者早期会出现淡漠等进行性行为改变或执行功能障碍；还有Down综合征早期会出现行为改变和执行功能障碍，对这些患者在筛查时需结合一些辅助检查如颞中回萎缩，异常的脑脊液生物标记(脑脊液Aβ浓度降低，总Tau蛋白浓度增高)、PET扫描结合MRI、直系亲属中有常染色体14号或21号显性突变等情况进行确诊。</p></sec></sec><sec id="s8"><title>4. 治疗</title><p>从AD目前的治疗看，还没有一种药物能够预防或减缓疾病进展的速度。主要是受到中晚期临床试验的困扰。目前有四种FDA批准的药物用于治疗AD的认知和功能障碍的药。尽管如此，近年来在阐明潜在病理学的关键方面取得了重大进展，新的治疗策略仍在积极开发和测试中。</p><sec id="s8_1"><title>4.1. 胆碱酯酶抑制剂(ChEIs)</title><p>乙酰胆碱是中枢神经系统中重要的神经递质之，通过对AD患者进行尸检及脑组织活检发现，乙酰胆碱递质减少，神经元功能异常。而ChEIs能阻断突触后膜上的胆碱酯酶水解乙酰胆碱递质，增加乙酰胆碱在中枢神经中的浓度。目前有三种ChEIs被批准用于轻度至中度AD，多奈哌齐、利伐他明和加兰他明。它们的主要药代动力学特征不同，多奈哌齐的半衰期比其他两种药的长，每日服用一次，这些药物都能改善AD患者的认知能力，然而他们对AD整体治疗作用不大，并不能改变疾病的进展，Han [<xref ref-type="bibr" rid="hanspub.38109-ref18">18</xref>] 等研究发现，对轻度认知障碍患者，在早期临床阶段应用ChEIs类药治疗会加重认知障碍。</p></sec><sec id="s8_2"><title>4.2. NMD受体拮抗剂</title><p>NMD受体是突触后膜上的离子通道蛋白，为特殊类型的谷氨酸类型递质神经受体。NMDA受体可影响神经元回路的形成，支配学习和记忆等功能。研究发现 [<xref ref-type="bibr" rid="hanspub.38109-ref19">19</xref>] Aβ能够通过NMDA诱导过量的钙进入神经元，导致突触功能障碍，进而导致神经元重新进入分裂周期，这是AD神经元死亡的前期。而NMDA抑制剂能显著减少Aβ蛋白沉积，降低tau蛋白的过度磷酸化，通过减少小角质细胞的过度激活来减少炎症因子，进而保护神经细胞。美金刚为NMDA受体拮抗药，Matsunaga [<xref ref-type="bibr" rid="hanspub.38109-ref20">20</xref>] 等研究发现美金刚能显著改善AD患者的认知功能及神经精神症状，对中重度AD患者联合ChEIs类药治疗优于单纯应用ChEIs类药。然而NMDA受体拮抗药与ChEIs类药物一样，其作用范围很小，而且该药物对长期疾病进展没有效果。因此，不建议给轻度AD患者用这种药。</p></sec><sec id="s8_3"><title>4.3. 针对Aβ蛋白抑制作用的药</title><p>目前，公认的是Aβ蛋白的积聚触发了AD的发病机制，因此，降低AD脑实质Aβ沉积的浓度可能会减缓疾病的进展，由于没有完整的AD动物模型来明确检验Aβ假说的有效性，只能通过研发疫苗来进行主动和被动免疫策略，以及分泌酶抑制剂的已成为临床试验中主要的靶向抗体模式。进二十年来，各大医药企业都进行了免疫试剂的研发，大部分药物均在实验阶段未取得成功，主要因疗效不佳或认知功能恶化，还有药物不良反应严重而不得不停止 [<xref ref-type="bibr" rid="hanspub.38109-ref21">21</xref>]。Aducanumab，为美国百健公司研发的一款单抗体药物，该药物能够透过血脑屏障，能有效阻止Aβ的积聚，目前已完成了第二阶段的临床试验，最近在第三阶段试验中对APOE4/4的早期AD纯合子患者显示了适度但显著的疗效 [<xref ref-type="bibr" rid="hanspub.38109-ref22">22</xref>]。</p></sec><sec id="s8_4"><title>4.4. 调节脑肠轴药物</title><p>由于肠道菌群与中枢神经系统之间可通过脑肠轴相互影响，与AD的发病相关。甘露特钠胶囊(GV-971)是以海洋褐藻提取物为原料制备获得的低分子酸性寡糖化物。通过重塑肠道菌群平衡，抑制肠道菌群特定代谢产物的异常增多，减少外周及中枢炎症，降低β淀粉样蛋白沉积和Tau蛋白过度磷酸化，从而改善认知功能障碍 [<xref ref-type="bibr" rid="hanspub.38109-ref14">14</xref>]。根据三期临床结果显示该药可改善轻度至中度阿尔茨海默症患者认知功能障碍，具有起效快、呈持续稳健改善的特点，安全性好。该药于2019年11月已获我国国家药品监督管理局批准，即将上市，为AD患者治疗带来新希望 [<xref ref-type="bibr" rid="hanspub.38109-ref23">23</xref>]。</p></sec><sec id="s8_5"><title>4.5. 年轻血液</title><p>Katsimpardi [<xref ref-type="bibr" rid="hanspub.38109-ref24">24</xref>] 等在实验研究中发现，在老年小鼠中引入年轻血液可改善与年龄相关的认知障碍，注射人脐带血后也可达到这种效果。研究发现，幼年小鼠血清促进了人神经元和功能性突触数量的增加，突触对刺激的反应增强，NMDA突触反应增强，老年小鼠血清或胎牛血清(FBS)均未见上述作用 [<xref ref-type="bibr" rid="hanspub.38109-ref24">24</xref>]。血浆交换目前尚在临床研究阶段，能起到去除旧血中有害血浆成分或刺激脑脊液产生抗体的作用，但不能提供治疗因子。</p></sec></sec><sec id="s9"><title>5. 研究发展</title><p>虽然到目前为止，还没有一种药物能够预防或减缓AD进展，但是相信随着神经影像技术，疾病动物模型，基因研究和生物标志物的技术持续改进，人们对AD病因机理的深入研究，新的治疗药物不断研发，在不久的将来，人们一定能够发现阻断AD疾病进展的药物。</p></sec><sec id="s10"><title>文章引用</title><p>李晓峰,司冰心,王广才,杜文津. 阿尔茨海默病的临床研究进展Clinical Research Progress of Alzheimer’s Disease[J]. 临床医学进展, 2020, 10(10): 2254-2259. https://doi.org/10.12677/ACM.2020.1010341</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38109-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zvěřová, M. (2019) Clinical Aspects of Alzheimer’s Disease. Clinical Biochemistry, 72, 3-6.  
&lt;br&gt;https://doi.org/10.1016/j.clinbiochem.2019.04.015</mixed-citation></ref><ref id="hanspub.38109-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Butcher, H.K., Holkup, P.A. and Buckwalter, K.C. (2001) The Experience of Caring for a Family Member with Alzheimer’s Disease. Western Journal of Nursing Research, 23, 33-55. &lt;br&gt;https://doi.org/10.1177/019394590102300104</mixed-citation></ref><ref id="hanspub.38109-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Alzheimer’s Association (2018) Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement, 14, 367-429.  
&lt;br&gt;https://doi.org/10.1016/j.jalz.2018.02.001</mixed-citation></ref><ref id="hanspub.38109-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chhatwal, J.P., Schultz, A.P., Johnson, K.A., et al. (2018) Preferential Degradation of Cognitive Networks Differentiates Alzheimer’s Disease from Ageing. Brain, 141, 1486-1500. &lt;br&gt;https://doi.org/10.1093/brain/awy053</mixed-citation></ref><ref id="hanspub.38109-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">O’Bryant, S.E., Mielke, M.M., Rissman, R.A., et al. (2017) Blood-Based Biomarkers in Alzheimer Disease: Current State of the Science and a Novel Collaborative Paradigm for Advancing from Discovery to Clinic. Alzheimer’s Dement, 13, 45-58. &lt;br&gt;https://doi.org/10.1016/j.jalz.2016.09.014</mixed-citation></ref><ref id="hanspub.38109-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kumfor, F. and Piguet, O. (2013) Emotion Recognition in the Dementias: Brain Correlates and Patient Implications. Neurodegenerative Disease Management, 3, 277-288. &lt;br&gt;https://doi.org/10.2217/nmt.13.16</mixed-citation></ref><ref id="hanspub.38109-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Aschenbrenner, A.J., Gordon, B.A., Benzinger, T.L.S., et al. (2018) Influence of Tau PET, Amyloid PET, and Hippocampal Volume on Cognition in Alzheimer Disease. Neurology, 91, e859-e866.  
&lt;br&gt;https://doi.org/10.1212/WNL.0000000000006075</mixed-citation></ref><ref id="hanspub.38109-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hanseeuw, B.J., Betensky, R.A., Jacobs, H.I.L., et al. (2019) Association of Amyloid and Tau with Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurology, 76, 915-924.  
&lt;br&gt;https://doi.org/10.1001/jamaneurol.2019.1424</mixed-citation></ref><ref id="hanspub.38109-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bussy, A., Snider, B.J., Coble, D., et al. (2019) Dominantly Inherited Alzheimer Network (2019). Effect of Apolipoprotein E4 on Clinical, Neuroimaging, and Biomarker Measures in Noncarrier Participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 75, 42-50. &lt;br&gt;https://doi.org/10.1016/j.neurobiolaging.2018.10.011</mixed-citation></ref><ref id="hanspub.38109-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bien-Ly, N., Gillespie, A.K., Walker, D., et al. (2012) Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Ab Accumulationin Mutant Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 32, 4803-4811. &lt;br&gt;https://doi.org/10.1523/JNEUROSCI.0033-12.2012</mixed-citation></ref><ref id="hanspub.38109-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Q., Lee, C.Y.D., Mandrekar, S., et al. (2008) ApoE Promotes the Proteolytic Degradation of Abeta. Neuron, 58, 681-693. &lt;br&gt;https://doi.org/10.1016/j.neuron.2008.04.010</mixed-citation></ref><ref id="hanspub.38109-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Simonsen, A.H., Herukka, S.K., Andreasen, N., et al. (2017) Recommendations for CSF AD Biomarkers in the Diagnostic Evaluation of Dementia. Alzheimer’s Dement, 13, 274-284. &lt;br&gt;https://doi.org/10.1016/j.jalz.2016.09.008</mixed-citation></ref><ref id="hanspub.38109-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Carbone, I., Lazzarotto, T., Ianni, M., et al. (2014) Herpes Virus in Alzheimer’s Disease: Relation to Progression of the Disease. Neurobiology of Aging, 35, 122-129. &lt;br&gt;https://doi.org/10.1016/j.neurobiolaging.2013.06.024</mixed-citation></ref><ref id="hanspub.38109-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">魏佳慧, 赵峰, 董靖玮, 等. 肠道菌群与阿尔茨海默病的相关性研究进展[J]. 临床医学进展, 2019, 9(5): 703-710.</mixed-citation></ref><ref id="hanspub.38109-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Perry, R.J., Watson, P. and Hodges, J.R. (2000) The Nature and Staging of Attention Dysfunction in Early (Minimal and Mild) Alzheimer’s Disease: Relationship to Episodic and Semantic Memory Impairment. Neuropsychologia, 38, 252-271. &lt;br&gt;https://doi.org/10.1016/S0028-3932(99)00079-2</mixed-citation></ref><ref id="hanspub.38109-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wilkinson, D. and Andersen, H. (2007) Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders, 24, 138-145. &lt;br&gt;https://doi.org/10.1159/000105162</mixed-citation></ref><ref id="hanspub.38109-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wattmo, C., Wallin, A.K., Londos, E., et al. (2011) Predictors of Long-Term Cognitive Outcome in Alzheimer’s Disease. Alzheimer’s Research &amp; Therapy, 3, 23. &lt;br&gt;https://doi.org/10.1186/alzrt85</mixed-citation></ref><ref id="hanspub.38109-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Han, J.Y., Besser, L.M., Xiong, C., et al. (2019) Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. Alzheimer Disease &amp; Associated Disorders, 33, 87-94.  
&lt;br&gt;https://doi.org/10.1097/WAD.0000000000000291</mixed-citation></ref><ref id="hanspub.38109-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.S., et al. (1992) Open-Channel Block of N-methyl-D-aspartate (NMDA) Responses by Memantine: Therapeutic Advantage against NMDA Receptor-Mediated Neurotoxicity. Journal of Neuroscience, 12, 4427-4436.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.12-11-04427.1992</mixed-citation></ref><ref id="hanspub.38109-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Matsunaga, S., Kishi, T. and Iwata, N. (2015) Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta Analysis. PLoS ONE, 10, e0123289. &lt;br&gt;https://doi.org/10.1371/journal.pone.0123289</mixed-citation></ref><ref id="hanspub.38109-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Paul, V.F., David, S., Elliott, D.B., et al. (2019) New Approaches for the Treatment of Alzheimer’s Disease. Bioorganic Medicinal Chemistry Letters, 29, 125-133. &lt;br&gt;https://doi.org/10.1016/j.bmcl.2018.11.034</mixed-citation></ref><ref id="hanspub.38109-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Martin, T., Susan, A. and Marwan, S. (2019) The Path Forward in Alzheimer’s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis. Alzheimer’s Dementia, 1-8.</mixed-citation></ref><ref id="hanspub.38109-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">周杰. 阿尔茨海默病新药: 中国原研另辟蹊径[J]. 新民周刊, 2019(43): 54-58.</mixed-citation></ref><ref id="hanspub.38109-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Katsimpardi, L., Litterman, N.K., Schein, P.A., et al. (2014) Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors. Science, 344, 630-634. &lt;br&gt;https://doi.org/10.1126/science.1251141</mixed-citation></ref></ref-list></back></article>